COMMUNIQUÉS West-GlobeNewswire

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
30/06/2026
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusions Composite complete [...]
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
30/06/2026
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. ( [...]
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
30/06/2026
Company now compliant with all continued listing rules for Nasdaq MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage [...]
BellaSeno’s regenerative scaffolds signal new era for breast surgery
30/06/2026
MedTech company, BellaSeno, is accelerating human trials of its proprietary breast scaffolds as it moves regenerative breast surgery toward clinical adoption LEIPZIG, Germany and SYDNEY, June 30, 2026 (GLOBE NEWSWIRE [...]
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
30/06/2026
Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children with preexisting genu [...]
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
30/06/2026
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) ( [...]
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
30/06/2026
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR [...]
Jushi Celebrates Enactment of Virginia Adult-Use Cannabis Legislation
30/06/2026
BOCA RATON, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (CSE: JUSH ) (OTCQX: JUSHF ) ("Jushi" or the "Company"), a vertically integrated, multi-state cannabis operator, celebrates the enactment of [...]
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
30/06/2026
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- [...]
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
30/06/2026
Expanding manufacturing capabilities is part of the Company’s cost reduction strategy and supports global expansion HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and [...]
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
30/06/2026
New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license. KNOXVILLE, Tenn [...]
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
30/06/2026
Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers Across both studies, mogamulizumab was associated with improved survival [...]
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
30/06/2026
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “ [...]
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
30/06/2026
Allowed Claims Cover a Method of Treating Netherton Syndrome with a Topical Serine Protease Inhibitor and an Anti-Inflammatory Agent, Including in Patients with SPINK5 Mutations ASHBURN, Va., June 30, 2026 (GLOBE [...]
NurExone Announces Closing of Non-Brokered Private Placement
30/06/2026
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based [...]
Les échafaudages régénératifs de BellaSeno annoncent l’avènement d’une nouvelle ère pour la chirurgie mammaire
30/06/2026
L’entreprise de technologies médicales BellaSeno intensifie son programme d’essais cliniques dans le domaine des échafaudages mammaires exclusifs, tandis que la chirurgie mammaire régénérative progresse vers une [...]
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
30/06/2026
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient development plan to [...]
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
30/06/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar [...]

Pages